Blinatumomab: First Global Approval

Blinatumomab (BLINCYTO™) is a novel, bispecific T-cell engaging antibody that binds cluster of differentiation (CD) 19 antigens on blast cells while also binding and activating the CD3/T cell receptor complex, causing cell lysis. The antibody is being developed by Amgen as a treatment for haematolog...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2015-02, Vol.75 (3), p.321-327
1. Verfasser:	Sanford, Mark
Format:	Artikel
Sprache:	eng
Schlagworte:	Agreements Antibodies Antibodies, Bispecific - administration & dosage Antibodies, Bispecific - adverse effects Antibodies, Bispecific - pharmacokinetics Antibodies, Bispecific - therapeutic use Antigens Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Cancer Chromosomes Clinical trials Clinical Trials as Topic Collaboration Drug Approval European Union FDA approval Hematology Humans Internal Medicine Leukemia Lymphocytes Lymphoma Medicine Medicine & Public Health Pharmacology/Toxicology Pharmacotherapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy R&D R&D Insight Report Remission (Medicine) Research & development T cell receptors United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!